Singaporean Telehealth Platform ORA Raises $10 Million USD Series A to Modernise Healthcare in the Region

The funding will be used to double down on the centralised software platform, geographical expansion and development of a new consumer healthcare offering

Singaporean telehealth platform ORA has raised a $10 million USD Series A funding. This is the largest telehealth Series A in South-East Asia and was co-led by TNB Aura and Antler with participation from Gobi Partners, Kairous Capital and GMA Ventures, bringing total funding to date above $17 million USD.

ORA is the fastest-growing and biggest vertically-integrated telehealth platform in South East Asia delivering over 250,000 consultations and has experienced uninterrupted monthly growth since its 2021 launch.

ORA has launched three brands that serve the modern patient living with chronic conditions, making treatment more accessible, convenient and personal. Modules is a first to market online dermatology experience making personalised, prescription skincare accessible with 676 different formulations, andSons offers male health solutions and OVA delivers female reproductive healthcare.

Founded by former ZALORA CMO Elias Pour, ORA is uniquely positioned with a diverse, proven leadership team with rich backgrounds across health, tech and consumer brands. Backed by a robust medical advisory board, ORA’s R&D team draws on experience from L’Oréal and Sephora creating high-touch products and experiences that are IP’d and 100% in-house developed.

With a strong attention to customer experience, first to market solutions like Modules, andSons and Ova are meeting modern customer expectations head on. These interactions are translating into deeper patient relationships, building retention rates only rivalled by subscription models like Netflix and unrivalled within the industry.

90% of ORA’s patients are first to condition, under 38 years old and have never been treated before. The disconnect between this younger patient population and the traditional healthcare model is ORA’s biggest opportunity. These new patients have a different set of demands such as flexibility and speed which ORA’s telemedicine model is perfectly placed to treat. ORA’s seamless end-to-end experience joins up the fragmented traditional model, linking consultation, education, pharmacy, delivery and post purchase care for unparalleled convenience.

“ORA is on a mission to deliver high touch, high-quality care to millions of patients and with our continued growth story throughout SEA, we are thrilled with today’s announcement.” said Elias Pour, ORA’s founder and CEO. “ORA has had over 6 million patient touch points provide us with valuable health data through extensive health evaluations and consultation online. This has brought unique insights into these patient’s healthcare expectations that has and will inform future innovations with our key partners.”

“We have the high growth potential of DTC, with a very high percentage of healthcare expenditure in our region being out of pocket. This is powered by an underlying SAAS type of recurring revenue, with subscriptions counting for more than 70% of our revenue and our retention is better than Netflix with 10x the monthly order value. We achieved post marketing breakeven at the end of last year on a group level after just 20 months of going live and have a very clear and believable path to profitability that is imminently ahead of us.

With this new round of funding ORA will seek to expand its presence into new territories, both geographically and with new offerings. Later this year ORA’s brands will arrive in retail across 1300 tier one stores bringing its accessible, medically-backed range of products to shelves. Looking at different geographies there are opportunities to expand into regions like the GCC.

Charles Wong, Founding Partner at TNB Aura commented: “Since ORA’s early days, TNB Aura has been a firm believer and strong supporter of Elias and the ORA team in their unwavering mission to provide access to affordable high-quality healthcare. Their combined focus on specialised, and often taboo, healthcare verticals as well as a direct-to-patient approach has led the team to clearly differentiate itself while delivering market-leading unit economics that meet the tailored needs of patients across the full value chain.”

Teddy Himler – Global Partner at Antler added: “Elias and team have learned from the extraordinary rise of telehealth globally and have applied it masterfully to the idiosyncratic (and often challenging) South East Asia region. We are inspired and supportive of their mission to become the “ Healthcare House of Brands” for the ~1B people in South East Asia and GCC who are underserved by the traditional healthcare system. We think ORA’s platform approach is the future of direct-to-patient healthcare globally.”

SourceORA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version